Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy

被引:4
作者
Albinsaad, Loai Saleh [1 ,2 ]
Kim, Jisun [2 ]
Chung, Il Yong [2 ]
Ko, Beom Seok [2 ]
Kim, Hee Jeong [2 ]
Lee, Jong Won [2 ]
Son, Byung Ho [2 ]
Ahn, Sei-Hyun [2 ]
Lee, Sae Byul [2 ]
机构
[1] King Faisal Univ, Coll Med, Dept Surg, Al Ahsa City, Eastern Prov, Saudi Arabia
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Div Breast Surg,Dept Surg, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea
关键词
Immunohistochemistry; Neoadjuvant therapy; Prognosis; Breast neoplasms; Tumor suppressor protein p53;
D O I
10.1007/s10549-021-06134-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of this study was to determine whether the outcome to neoadjuvant chemotherapy (NAC) can be predicted by analyzing p53 expression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients. Methods We retrospectively reviewed 594 patients diagnosed with stage I-III HR-positive, HER2-negative breast cancer, and treated with NAC at the Asan Medical Center between 2008 and 2014. Expression of p53 was assessed, and overall survival (OS) and breast cancer-specific survival (BCSS) were investigated and compared between groups. Results At a median follow-up period of 69.8 months, OS and BCSS were higher in the p53-negative (p53(-)) group than in the p53-positive (p53(+)) group. Five-year OS was 95.4% in the p53(-) and 92.1% in the p53(+) group (p = 0.005). BCSS was 96.2% in the p53(-) group and 93% in the p53(+) group (p = 0.008). Conclusion High expression of immunohistochemically detected p53 was strongly and significantly associated with decreased OS and BCSS than low p53 expression, suggesting that p53 may be a powerful prognostic factor in HR-positive, HER2-negative breast cancer patients receiving NAC.
引用
收藏
页码:447 / 454
页数:8
相关论文
共 19 条
  • [1] Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression
    Abubakar, Mustapha
    Guo, Changyuan
    Koka, Hela
    Sung, Hyuna
    Shao, Nan
    Guida, Jennifer
    Deng, Joseph
    Li, Mengjie
    Hu, Nan
    Zhou, Bin
    Lu, Ning
    Yang, Xiaohong R.
    [J]. NPJ BREAST CANCER, 2019, 5 (1)
  • [2] Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
    Bae, Soo Youn
    Lee, Jeong Hyeon
    Bae, Jeoung Won
    Jung, Seung Pil
    [J]. ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) : 291 - 298
  • [3] Barbareschi, 1996, PROGN VALUE IMMUNOHI, V4, P106
  • [4] Clinical outcomes based on multigene profiling in metastatic breast cancer patients
    Basho, Reva K.
    Gagliato, Debora de Melo
    Ueno, Naoto T.
    Wathoo, Chetna
    Chen, Huiqin
    Shariati, Maryam
    Wei, Caimiao
    Alvarez, Ricardo H.
    Moulder, Stacy L.
    Sahin, Aysegul A.
    Roy-Chowdhuri, Sinchita
    Chavez-MacGregor, Mariana
    Litton, Jennifer K.
    Valero, Vincent
    Luthra, Raja
    Zeng, Jia
    Shaw, Kenna R.
    Mendelsohn, John
    Mills, Gordon B.
    Tripathy, Debu
    Meric-Bernstam, Funda
    [J]. ONCOTARGET, 2016, 7 (47) : 76362 - 76373
  • [5] Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
    Bertheau, P
    Plassa, F
    Espié, M
    Turpin, E
    de Roquancourt, A
    Marty, M
    Lerebours, F
    Beuzard, Y
    Janin, A
    de Thé, H
    [J]. LANCET, 2002, 360 (9336) : 852 - 854
  • [6] Third consensus on medical treatment of metastatic breast cancer
    Beslija, S.
    Bonneterre, J.
    Burstein, H. J.
    Cocquyt, V.
    Gnant, M.
    Heinemann, V.
    Jassem, J.
    Koestler, W. J.
    Krainer, M.
    Menard, S.
    Petit, T.
    Petruzelka, L.
    Possinger, K.
    Schmid, P.
    Stadtmauer, E.
    Stockler, M.
    Van Belle, S.
    Vogel, C.
    Wilcken, N.
    Wiltschke, C.
    Zielinski, C. C.
    Zwierzina, H.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (11) : 1771 - 1785
  • [7] Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status
    Bouchalova, Pavla
    Nenutil, Rudolf
    Muller, Petr
    Hrstka, Roman
    Appleyard, M. Virginia
    Murray, Karen
    Jordan, Lee B.
    Purdie, Colin A.
    Quinlan, Philip
    Thompson, Alastair M.
    Vojtesek, Borivoj
    Coates, Philip J.
    [J]. JOURNAL OF PATHOLOGY, 2014, 233 (03) : 238 - 246
  • [8] Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
    Boughey, Judy C.
    McCall, Linda M.
    Ballman, Karla V.
    Mittendorf, Elizabeth A.
    Ahrendt, Gretchen M.
    Wilke, Lee G.
    Taback, Bret
    Leitch, A. Marilyn
    Flippo-Morton, Teresa
    Hunt, Kelly K.
    [J]. ANNALS OF SURGERY, 2014, 260 (04) : 608 - 616
  • [9] Prognostic and predictive factors in early-stage breast cancer
    Cianfrocca, M
    Goldstein, LJ
    [J]. ONCOLOGIST, 2004, 9 (06) : 606 - 616
  • [10] Clarke M, 1998, LANCET, V351, P1451